Castle Biosciences Inc (CSTL) — Capital Reinvestment Ratio

Latest as of September 2025: 0.66x

Castle Biosciences Inc (CSTL) has a Capital Reinvestment Ratio of 0.66x as of September 2025, meaning it reinvests 1% of its operating cash flow ($22.63 Million) in capital expenditures ($14.83 Million). See CSTL net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.66x
Capex / Operating Cash Flow

Operating Cash Flow

$22.63 Million
USD

Capital Expenditures

$14.83 Million
USD

Data as of

Sep 2025
Most recent filing

Castle Biosciences Inc Capital Reinvestment Ratio (2019–2024)

This chart tracks Castle Biosciences Inc's Capital Reinvestment Ratio across 3 annual periods. Check how aggressively does Castle Biosciences Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Castle Biosciences Inc (2019–2024)

Year-by-year Capital Reinvestment Ratio for Castle Biosciences Inc from 2019 to 2024. For live market cap and broader valuation context, see CSTL company net worth.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2024 0.44x $64.87 Million $28.33 Million ▼ -9.3%
2020 0.48x $9.87 Million $4.75 Million ▲ +260.6%
2019 0.13x $7.01 Million $937.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow